News articles about Global Blood Therapeutics (NASDAQ:GBT) have been trending somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Global Blood Therapeutics earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned media stories about the company an impact score of 43.8737875924016 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news articles that may have impacted Accern Sentiment’s rankings:

Several research analysts have commented on the company. Oppenheimer set a $53.00 price target on Global Blood Therapeutics and gave the stock a “buy” rating in a research report on Monday, October 23rd. ValuEngine lowered Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. BidaskClub raised Global Blood Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, November 1st. Janney Montgomery Scott began coverage on Global Blood Therapeutics in a research report on Tuesday. They set a “buy” rating and a $75.00 price target on the stock. Finally, Zacks Investment Research raised Global Blood Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, December 6th. Two analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $65.80.

Global Blood Therapeutics (NASDAQ GBT) opened at $62.30 on Thursday. The stock has a market capitalization of $2,780.00 and a P/E ratio of -24.43. Global Blood Therapeutics has a twelve month low of $21.85 and a twelve month high of $65.40.

In related news, major shareholder Perceptive Advisors Llc bought 175,000 shares of the company’s stock in a transaction dated Tuesday, December 19th. The shares were acquired at an average price of $38.00 per share, with a total value of $6,650,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Peter Radovich sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $60.00, for a total value of $1,800,000.00. Following the completion of the transaction, the insider now directly owns 33,581 shares in the company, valued at approximately $2,014,860. The disclosure for this sale can be found here. In the last three months, insiders sold 51,812 shares of company stock worth $2,864,728. Corporate insiders own 5.30% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Global Blood Therapeutics (GBT) Getting Somewhat Favorable Media Coverage, Report Finds” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Insider Buying and Selling by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with's FREE daily email newsletter.